The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial
- 1 August 2006
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 368 (9534), 476-482
- https://doi.org/10.1016/s0140-6736(06)69155-1
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Baseline HIV‐1 RNA Level and CD4 Cell Count Predict Time to Loss of Virologic Response to Nelfinavir, but Not Lopinavir/Ritonavir, in Antiretroviral Therapy–Naive PatientsThe Journal of Infectious Diseases, 2004
- Treatment for Adult HIV InfectionJAMA, 2004
- Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive PatientsA 3-Year Randomized TrialJAMA, 2004
- SOLOAIDS, 2004
- Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 InfectionNew England Journal of Medicine, 2004
- GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patientsAIDS, 2004
- Incidence of Resistance in a Double‐Blind Study Comparing Lopinavir/Ritonavir Plus Stavudine and Lamivudine to Nelfinavir plus Stavudine and LamivudineThe Journal of Infectious Diseases, 2004
- Decline in the AIDS and death rates in the EuroSIDA study: an observational studyThe Lancet, 2003
- Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: 2003 Recommendations of an International AIDS Society–USA PanelClinical Infectious Diseases, 2003
- Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV InfectionNew England Journal of Medicine, 2002